These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 16981822)
1. The therapeutic potential of CD39: interview with Dr Simon Robson by Emma Quigley. Robson S Expert Opin Ther Targets; 2006 Oct; 10(5):649-52. PubMed ID: 16981822 [TBL] [Abstract][Full Text] [Related]
2. Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets. Atkinson B; Dwyer K; Enjyoji K; Robson SC Blood Cells Mol Dis; 2006; 36(2):217-22. PubMed ID: 16476557 [TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3--a promising therapeutic target: Dr Hagit Eldar-Finkelman interviewed by Emma Quigley. Eldar-Finkelman H Expert Opin Ther Targets; 2006 Apr; 10(2):199-201. PubMed ID: 16548769 [TBL] [Abstract][Full Text] [Related]
4. Cell adhesion molecules as therapeutic targets: interview with Professor Michael P Schön. Interviewed by Emma Quigley. Schön MP Expert Opin Ther Targets; 2006 Dec; 10(6):799-802. PubMed ID: 17105368 [TBL] [Abstract][Full Text] [Related]
5. Inhibiting angiogenesis: interview with Dr Jean Plouët. Interview by Emma Quigley. Plouët J Expert Opin Ther Targets; 2006 Aug; 10(4):501-3. PubMed ID: 16848687 [TBL] [Abstract][Full Text] [Related]
6. A new therapeutic target for atherosclerosis treatment: interview with Uday Saxena. Interviewed by Emma Quigley. Saxena U Expert Opin Ther Targets; 2006 Feb; 10(1):1-3. PubMed ID: 16441223 [TBL] [Abstract][Full Text] [Related]
7. Current targets in irritable bowel syndrome: an interview with Eamonn Quigley. Interview by Emma Quigley. Quigley E Expert Opin Ther Targets; 2006 Jun; 10(3):351-3. PubMed ID: 16706675 [TBL] [Abstract][Full Text] [Related]
15. Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. Jackson SW; Hoshi T; Wu Y; Sun X; Enjyoji K; Cszimadia E; Sundberg C; Robson SC Am J Pathol; 2007 Oct; 171(4):1395-404. PubMed ID: 17823293 [TBL] [Abstract][Full Text] [Related]
16. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. Reutershan J; Vollmer I; Stark S; Wagner R; Ngamsri KC; Eltzschig HK FASEB J; 2009 Feb; 23(2):473-82. PubMed ID: 18838482 [TBL] [Abstract][Full Text] [Related]
17. Regulation of the T Cell Response by CD39. Takenaka MC; Robson S; Quintana FJ Trends Immunol; 2016 Jul; 37(7):427-439. PubMed ID: 27236363 [TBL] [Abstract][Full Text] [Related]
18. Suppression of ATP diphosphohydrolase/CD39 in human vascular endothelial cells. Imai M; Kaczmarek E; Koziak K; Sévigny J; Goepfert C; Guckelberger O; Csizmadia E; Schulte Am Esch J; Robson SC Biochemistry; 1999 Oct; 38(41):13473-9. PubMed ID: 10521254 [TBL] [Abstract][Full Text] [Related]
19. Making melanoma therapy personal: an interview with Dr Keiran Smalley for Smalley KS Melanoma Manag; 2017 May; 4(2):95-97. PubMed ID: 30190911 [TBL] [Abstract][Full Text] [Related]
20. Loss of purinergic vascular regulation in the colon during colitis is associated with upregulation of CD39. Neshat S; deVries M; Barajas-Espinosa AR; Skeith L; Chisholm SP; Lomax AE Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G399-405. PubMed ID: 19074640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]